Citations

Clear

4510 citation(s) found for "Scott, C".

AAPM task group report 210: Conventional linear accelerator acceptance testing
Pérez-Andújar, A, Narayanasamy, Ganesh, Huang, Ellen , Li, Hua , Morrow, A, Rangaraj, D, Schupp, Nicholas, Yaddanapudi, Sridhar , Yan, Guanghua, Yang, Ching‐Chong Jack, Yaddanapudi, Sridhar , Holmes, Todd, Yan, Guanghua

Mayo Clinic

Medical Physics | October 22, 2025 | Volume: 52 | Issue: 11 | Pages: No page available

10.1002/mp.70047 Get It

Abstract Increased demand to make medical linear accelerator acceptance testing procedures (ATP) more efficient exists while the technology being evaluated for clinical use has become increasingly complex. The most recent American Association of Physicists in Medicine (AAPM) task group giving guidelines to medical physicists on ATP was Task Group report 45, published in 1994. Several new technologies, enhanced machine performance, and possible future changes to ATP since that time require updated guidance from the AAPM. The goal of this task group is to empower the medical physicist to be meaningfully involved with the design and execution of comprehensive and effective linear accelerator ATP beginning with the purchasing contract negotiation to the contractual handover of the linear accelerator to the department for clinical use. Additionally, we discussed aspects related to beam matching, ATP at the time of replacing major linear accelerator's components as well as what we perceive as the future of the ATP process given the trends of standardizing linear accelerators.
Who Shapes the Future of Health Communication? Networks, Silos, and New Imperatives in the Digital Age
Britt, Rebecca K. , Franco, Courtny L. , Sams, Amanda, Ginwal, Priyanka , Obregón, Rafael , Ratzan, Scott C. , Ivic, Rebecca K , Franco, Courtny, Rubinelli, Sara , Sams, Amanda

Mayo Clinic

Journal of Health Communication | October 22, 2025 | Volume: 30 | Issue: 10-12 | Pages: 522-527

10.1080/10810730.2025.2574675 | PMID 41121593 Get It

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup
Lone, Waseem , Yu, Jiayu , Liu, Xuxiang , Jochum, Dylan T. , Bouska, Alyssa , Shetty, Kunal , Herek, Tyler A. , Sharma, Sunandini , Bi, Chengfeng , Shah, Ab Rauf , Nasser, Zaina W., Amador, Catalina , Arif, Aiza, Mir, Abdul Rouf , Li, Yuping , Heavican‐Foral, Tayla B. , Robinson, Jacob E. , Hyde, R. Katherine , Sakata‐Yanagimoto, Mamiko , Rachagani, Satyanarayana , McKeithan, Timothy W. , Scott, David W. , Staudt, Louis M. , Feldman, Andrew L. , Greiner, Timothy C. , Vose, Julie M. , Khoury, Joseph D. , Chan, Wing C. , Iqbal, Javeed , Lone, Waseem G , Shah, Rauf , Feldman, Andrew L , Greiner, Timothy C , Vose, Julie , Rimsza, Lisa, Khoury, Joseph , Chan, Wing C , Iqbal, Javeed , Scott, David W , Bouska, Alyssa , Amador, Catalina , Jochum, Dylan , Heavican, Tayla B., Robinson, Jacob, Inghirami, Giorgio , Rimsza, Lisa M.

Mayo Clinic

Science Advances | October 17, 2025 | Volume: 11 | Issue: 42 | Pages: No page available

10.1126/sciadv.adx6877 | PMID 41105775 Get It

Peripheral T cell lymphoma (PTCL) is a heterogeneous group of postthymic T cell neoplasms, with ~40% classified as PTCL–not otherwise specified (PTCL-NOS). PTCL-GATA3, a molecularly defined subtype, associated with T helper 2 (T H 2)–like differentiation and poor prognosis, has frequent co-occurrence of TP53 loss/mutation and heterozygous PTEN loss. CD4+ T cell conditional mouse models with Trp53 mutation/deletion and Pten loss demonstrated mature T cell lymphomas (mTCLs) with T H 2-like transcriptomic and immunophenotypic profiles. Molecular studies revealed that codeletion of Trp53/Pten induced T cell receptor and Janus kinase–signal transducer and activator of transcription signaling, promoting T H 2 differentiation while inhibiting T H 1 differentiation. These findings were validated by CRISPR editing of TP53/PTEN loss in human CD4+ T cells and mechanistically evaluated the p53 binding region in intron-3 of GATA3, resulting in transcriptional repression. Transcriptomic profiles of m-TCLs recapitulated human-PTCL-GATA3 transcriptome and distinguished PTCL-NOS subtypes. Preclinical assessment of m-TCLs with PI3Kγ/δ inhibitors significantly improved survival, supporting a therapeutic approach for the p53-aberrant PTCL-GATA3.
Association between Serum Glycerol-3-Phosphate and Fibroblast Growth Factor-23 in Nondiabetic Patients on Hemodialysis
Wilson, Scott , Zaslow, Shari J. , Sozio, Stephen M. , Jaar, Bernard G. , Perwad, Farzana , Estrella, Michelle M. , Martin, Aline , Parekh, Rulan S. , Chen, Wei , Wilson, Scott M , Zaslow, Shari, Robinson-Cohen, Cassiane , Estrella, Michelle M , Martin, Aline , Parekh, Rulan S , Chen, Wei

Mayo Clinic

Clinical Journal of the American Society of Nephrology | October 17, 2025 | Volume: 21 | Issue: 2 | Pages: 211-220

10.2215/cjn.0000000871 | PMID 41105473 Get It

Key Points Serum glycerol-3-phosphate (G3P) levels were significantly associated with higher fibroblast growth factor 23 levels in ESKD. Pathway and mediation analyses identified the pentose phosphate pathway as the top mediator of the relationship between serum G3P and fibroblast growth factor 23. The role of G3P in ESKD provides new insights into potential therapeutic targets for CKD-mineral and bone disorder. Background Fibroblast growth factor 23 (FGF23) is a key regulator of mineral metabolism that is independently associated with mortality in patients with ESKD. Glycerol-3-phosphate (G3P), a byproduct of glycolysis that can be derived from injured kidneys, stimulates FGF23 production. We aimed to determine if serum G3P is associated with FGF23 levels in patients with ESKD and identify potential molecular pathways that mediate their relationship. Methods We conducted a cross-sectional study of 99 nondiabetic patients with ESKD on hemodialysis. We used linear regression to examine the association between G3P terciles and log-transformed C-terminal FGF23 levels, adjusting for demographics, coronary artery disease, serum calcium, phosphorus, and parathyroid hormone. Mann–Whitney U tests compared 247 serum metabolite levels between the first and third FGF23 terciles; significant metabolites ( P < 0.01) were selected for pathway enrichment analyses. Top pathway scores were used in mediation analyses. Results The median age of participants was 54 years (interquartile range [IQR], 44–63), 38% were women, 71% self-identified as Black, and 27% had coronary artery disease. The median FGF23 level was 777 (interquartile range, 222–1310) RU/ml. In adjusted analyses, compared with participants with the lowest G3P tercile, those with the highest G3P tercile had a 95% higher FGF23 level (95% Confidence Interval, 6% to 260%; P = 0.04). Of the 27 metabolites significantly associated with FGF23 levels, pathway enrichment analysis identified the pentose phosphate pathway as the top hit (impact score=0.33, false discovery rate-adjusted P value = 0.01). The pentose phosphate pathway mediated the relationship between G3P and FGF23, resulting in a 62% change in the β coefficient. Conclusions In nondiabetic patients with ESKD on hemodialysis, serum G3P positively correlated with serum C-terminal FGF23, and this relationship was mediated by the pentose phosphate pathway. Exploring the pentose phosphate pathway could yield critical mechanistic insights into the regulation of FGF23, enhancing our understanding of its broader biologic functions.
Leveraging Artificial Intelligence for the Diagnosis of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: Opportunities, Challenges, and Future Perspectives
Jain, Samiksha , Kaur, Avneet , Qadeer, Abdul , Ghosh, Victor , Thota, Shivani, Banala, Mallareddy , Lee, Jieun , Yerrapragada, Gayathri, Poonguzhali, E. , Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Kala, Jayavinamika Jayapradhaban, Richard, Samuel, Vommi, Saai Poornima, Karuppiah, Shiva Sankari, Muthyala, Anjani, Iyer, Vivek , Helgeson, Scott A. , Mitra, Dipankar , Arunachalam, Shivaram P. , Natarajan, Thangeswaran , Jayapradhaban Kala, Jayavinamika, Iyer, Vivek N , Arunachalam, S P , Helgeson, Scott A , Shariff, Mohammad Naveed , Qadeer, Abdul , Thota, Shivani

Mayo Clinic

Advances in Respiratory Medicine | October 17, 2025 | Volume: 93 | Issue: 5 | Pages: 47

10.3390/arm93050047 | PMID 41149139 Get It

Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a life-threatening vascular complication of SSc, marked by high morbidity and mortality. Early diagnosis remains a major challenge due to nonspecific symptoms and the limitations of conventional tools such as echocardiography (ECHO), pulmonary function tests (PFTs), and serum biomarkers. This review evaluates the emerging role of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), in improving the diagnostic landscape of SSc-PAH. A comprehensive literature search was conducted across PubMed, Scopus, IEEE Xplore, Embase and Google Scholar to identify studies involving AI applications in SSc, pulmonary arterial hypertension (PAH), and their intersection. Evidence indicates that AI models can assist interpretation across modalities, including heart sounds, ECGs, chest X-rays (CXRs), ECHOs, CT pulmonary angiography (CTPA), and omics-based biomarkers. While several models show encouraging diagnostic performance, their accuracy varies by dataset and modality, and most require external validation against right heart catheterization (RHC)-confirmed cohorts. Integrating multimodal data through AI frameworks may enhance early recognition and individualized risk stratification; however, these tools remain exploratory. Future work should emphasize harmonized hemodynamic definitions, transparent validation protocols, and SSc-specific datasets to ensure clinical applicability and reproducibility.
Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance
McGehee, Cordelia D. , Meng, X. Wei, Wu, Xinyan , Correia, Cristina , Venkatachalam, Annapoorna , Flatten, Karen S., Peterson, Kevin L. , Patel, Anand G. , Rossman, Olivia K., Wong, Clara, Hurley, Rachel M. , Wagner, Jill M., Schneider, Paula A., Hendrickson, Andrea E. Wahner , Swisher, Elizabeth M. , Dai, Haiming , Pandey, Akhilesh , Kaufmann, Scott H , Swisher, Elizabeth M , Correia, Cristina , Wong, Clara, Poirier, Guy G. , Pandey, Akhilesh , Li, Hu , Kaufmann, Scott H.

Mayo Clinic

Nucleic Acids Research | October 15, 2025 | Volume: 53 | Issue: 19 | Pages: No page available

10.1093/nar/gkaf990 | PMID 41099700 Get It

Abstract BRCA2 mutations contribute to the pathogenesis and treatment sensitivity of a subset of ovarian, breast, prostate, and pancreatic cancers. When these cancers become therapy resistant, secondary mutations that restore the BRCA2 open reading frame are found in half the cases, but other causes of resistance remain incompletely understood. Here, we identified translational readthrough of a premature termination codon (PTC) as a cause of resistance to poly(ADP-ribose) polymerase inhibitors (PARPis) and cisplatin in cells derived from the BRCA2-mutated ovarian cancer line PEO1 by PARPi selection. Despite persistence of the signature 4965C &gt; G (p.Y1655X) BRCA2 mutation, low-level expression of full-length BRCA2 protein was detectable in these cells by immunoblotting and tandem mass spectrometry. Either BRCA2 knockdown or gene interruption 5′ or 3′ to the PTC restored treatment sensitivity, implicating BRCA2 in the resistance. Reporter assays demonstrated UAG-selective readthrough in the resistant clones but not parental cells. Moreover, custom searching of global proteomic data indicated readthrough of stop codons, particularly UAGs, in additional proteins in the resistant clones. Finally, multi-omic analysis identified multiple changes in the nonsense-mediated decay and termination machineries that favor readthrough. Accordingly, the present results identify PTC readthrough as a potential mechanism of drug resistance in cells with BRCA2 nonsense mutations.
Histologic correlates of background parenchymal uptake on molecular breast imaging
Speltz, Lydia Bardwell, Ghosh, Karthik, Visscher, Daniel W., Cole, Kristin C., Kroneman, Trynda, Maxwell, Robert W. , Conners, Amy Lynn , Hunt, Katie N. , Rhodes, Deborah J. , Vachon, Celine M. , Speltz, Lydia J. Bardwell , Scott, Christopher G. , Cole, Kristin C., Vachon, Celine M. , Hruska, Carrie B.

Mayo Clinic

No container title available | October 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7724449/v1 Get It

Abstract Background Molecular breast imaging (MBI) has shown utility as a supplement to mammography in women with dense breasts. Background parenchymal uptake (BPU), which describes the level of Tc-99m sestamibi in fibroglandular tissue on MBI, varies among women with similar density. Higher BPU is associated with greater breast cancer risk. The goal of this work is to investigate the histological correlations of BPU that may explain this association with risk. Methods We compared histologic features of prospectively collected benign breast tissue biopsies from healthy women who had a region of dense tissue on mammography exhibiting one of the extreme categories of BPU on MBI: either photopenic or marked. Tissue composition of specimens was assessed by measuring area of epithelium, stroma, and fat and counting lobules. Lobular involution status was assessed by an expert pathologist as either none, partial, or complete. Ki-67 index and estrogen receptor-alpha expression were also assessed. Results Biopsies were performed in 48 women (mean age 54.9 years [SD 11.1 years]), including 20 with marked BPU and 28 with photopenic BPU. Women with marked BPU were younger (mean age 49.9 vs. 58.4 years, p = 0.004), had higher body mass index ( p = 0.01), and were more likely premenopausal ( p = 0.005). Marked BPU specimens had a higher proportion of epithelium (14.5% vs. 2.2%, p < 0.001), lower stromal content (44.8% vs. 84.2%, p = 0.005), similar fat (18.9% vs. 12.9%, p = 0.41), and greater lobule counts (15.5 vs. 6.3, p < 0.001) compared to photopenic specimens. Complete lobular involution was less frequent in marked tissue than in photopenic tissue (10.5% vs. 76%, p < 0.001). Ki-67 index was higher in marked BPU tissues (5.4% vs. 1.6%, p = 0.006), though the difference was attenuated after adjustment for epithelial area (p = 0.26). Estrogen receptor-alpha expression did not differ between marked and photopenic groups (25.6% vs. 28.4%, p = 0.12). Conclusions Marked BPU on MBI is associated with greater epithelial content, less lobular involution, and higher proliferative activity—features characteristic of tissue at elevated risk for malignant transformation. These findings suggest that BPU provides functional information beyond mammographic density, supporting its role as an imaging biomarker for breast cancer risk in women with dense breasts. Trial Registration: NCT01240278 and NCT01588834
In Reply: Are There Differences in 2-Year Outcomes Between 2-Level Anterior Cervical Diskectomy and Fusion Versus Single-Level Anterior Cervical Corpectomy and Fusion to Treat Cervical Myelopathy? A Quality Outcomes Database Study
Berlin, Connor , Mummaneni, Praveen V., Chan, Andrew K. , Chou, Dean , Fu, Kai-Ming, Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I. , Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Tumialán, Luis M. , Turner, Jay D. , Uribe, Juan S. , Haid, Regis W., Yen, Chun-Po , Shaffrey, Mark E., Ibrahim, Sufyan , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Neurosurgery | October 14, 2025 | Volume: 97 | Issue: 6 | Pages: e177-e178

10.1227/neu.0000000000003811 | PMID 41085387 Get It

Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women
Keil, Alexander P. , Taylor, Jack A. , Yadav, Siddhartha , Culver, Hoda Anton, Auer, Paul L. , Bodelón, Clara , Haiman, Christopher A., Lindströem, Sara, Martinez, Maria Elena, Nathanson, Katherine L. , Patel, Alpa V. , Penney, Kathryn L., Ruddy, Kathryn J. , Teras, Lauren R., Vachon, Celine M. , Weitzel, Jeffrey N. , Yao, Song, Weitzel, Jeffrey N , Yadav, Siddhartha , Taylor, Jack A , Nathanson, Katherine L , O’Brien, Katie M. , Weinberg, Clarice R. , Polley, Eric C. , Boddicker, Nicholas , Hu, Chunling , Ambrosone, Christine B. , Brantley, Kristen D. , Burnside, Elizabeth S. , Chen, Fei , Domchek, Susan M. , Eliassen, A. Heather , Hodge, James M. , Kraft, Peter , Lacey, James V. , Neuhausen, Susan L. , Olson, Janet E. , Palmer, Julie R. , Penney, Kathryn , Scott, Christopher G. , Teras, Lauren R. , Trentham‐Dietz, Amy , Vachon, Celine M. , Yao, Song , Zirpoli, Gary , Couch, Fergus J. , Sandler, Dale P.

Mayo Clinic

JAMA Oncology | October 9, 2025 | Volume: 11 | Issue: 12 | Pages: 1458

10.1001/jamaoncol.2025.3875 | PMID 41066089 Get It

Importance Inherited pathogenic variants (PVs) in known predisposition genes can greatly increase breast cancer risk, but the combined impact of PV status, family history, and other factors on breast cancer risk in the general US population has not been well described. Objective To evaluate population-based breast cancer risk estimates for those with established PVs overall and stratified by first-degree family history of breast cancer and other factors. Design, Setting, and Participants This study used pooled data from 13 US-based breast cancer case-control studies participating in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Enrollment for individual studies occurred between 1976 and 2013, and results are based on data released March 2023, with analyses conducted from June 2022 to July 2025. Exposures PVs, breast cancer family history, self-reported race and ethnicity, and established risk factors. Main Outcomes and Measures Breast cancer rate ratios for PVs in 7 genes were estimated from the CARRIERS consortium. PV status and incidence and mortality statistics were combined using the Individualized Coherent Absolute Risk Estimation (iCARE) model to estimate conditional cumulative breast cancer risks and 95% CIs, stratified by family history and standardized to the US population. Models that incorporated population-based data and published estimates for established epidemiologic risk factors were also evaluated. Results A total of 67 692 women were studied, including 33 841 who were diagnosed with breast cancer. PVs in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 were strongly associated with breast cancer risk, with BRCA1 and PALB2 PVs showing evidence of heterogeneity by family history. In models considering PVs, family history, and established risk factors, the estimated cumulative risks of breast cancer by age 50 years ranged from 2.4% (95% CI, 2.4-2.4) in women with no PVs and no family history to 35.5% (95% CI, 21.6-55.1) in PALB2 PV carriers with a family history. Among women who have not been diagnosed with breast cancer by age 50 years, the cumulative risk of breast cancer by age 80 years ranged from 11.1% (95% CI, 11.0-11.2) in noncarriers with no family history to 70.5% (95% CI, 52.8-83.5) for PALB2 carriers with a family history. PV-specific cumulative risk estimates varied across subgroups defined by race and ethnicity and potentially modifiable epidemiologic risk factors. Conclusions and Relevance In this study, population-based estimates of cumulative breast cancer risk for established PVs, as informed by the CARRIERS case-control sample, varied by family history and potentially modifiable risk factors. These estimates provide guidance for identifying individuals who will most benefit from enhanced screening and prevention strategies.
Discovery and Validation of Molecular Biomarkers for Differentiation of Nondysplastic Barrett’s Esophagus from High-grade Dysplasia and Esophageal Adenocarcinoma
Matchett, Caroline L. , Taylor, William R. , Berger, Calise K. , Anderson, Caryn E., Passe, Melissa, Lansing, Ramona, Wang, Panwen , Chalmers, Collin E., Foote, Patrick H. , Eckel‐Passow, Jeanette E. , Codipilly, Don C. , Leggett, Cadman L. , Ramirez, Francisco C. , Wolfsen, Herbert C. , Eluri, Swathi , Konda, Vani J. , Iyer, Prasad G. , Slettedahl, Seth W , Taylor, William R , Berger, Calise K , Anderson, Caryn E , Passe, Melissa A , Lansing, Ramona M , Wang, Panwen , Chalmers, Collin E , Foote, Patrick H , Eckel-Passow, Jeanette E , Sun, Zhifu , Mahoney, Douglas W , Codipilly, Don Chamil , Leggett, Cadman L , Ramirez, Francisco C , Kahn, Allon , Wolfsen, Herbert C , Eluri, Swathi , Konda, Vani , Trindade, Arvind J , Iyer, P G , Kisiel, John B , Slettedahl, Seth W. , Sun, Zhifu , Mahoney, Douglas W. , Kahn, Allon , Trindade, Arvind J. , Kisiel, John B.

Mayo Clinic

Cancer Prevention Research | October 8, 2025 | Volume: 19 | Issue: 1 | Pages: 49-60

10.1158/1940-6207.capr-25-0215 | PMID 41059926 Get It

Abstract Aberrant DNA methylation and copy-number alterations (CNA) drive Barrett’s esophagus progression to esophageal adenocarcinoma; however, their combined utility for early detection is unclear. We aimed to identify and validate methylated DNA markers (MDM) and CNAs to distinguish esophageal adenocarcinoma/high-grade dysplasia (HGD) from nondysplastic Barrett’s esophagus (NDBE). In this multiphase, multicenter study, we discovered and validated MDMs and quantified CNAs utilizing whole-genome methylation sequencing of esophageal brushings. DNA biomarkers identified from discovery were further validated in independent patients with paired esophageal brushing and swallowed capsule sponge samples. MDMs were filtered against a reduced representation bisulfite sequencing dataset obtained from independent tissue samples to advance only concordant candidates. CNA burden was quantified using ichorCNA-derived aneuploidy scores (AS). Two hundred MDMs discovered in HGD (N = 18) and esophageal adenocarcinoma (N = 18) versus NDBE brushing samples (N = 18) were tested in independent samples (N = 146). A 52-MDM panel achieved a cross-validated AUC of 0.88 [95% confidence interval (CI), 0.82–0.95]; the addition of AS improved discrimination of HGD/esophageal adenocarcinoma from NDBE to 0.91 (95% CI, 0.86–0.97) AUC. At 80% specificity, the combined model detected 93% of esophageal adenocarcinoma and 88% of HGD cases. In paired capsule sponge samples, a 58-MDM panel achieved a cross-validated AUC of 0.77 (95% CI, 0.66–0.88); a combined 58-MDM and AS model achieved AUC 0.80 (95% CI, 0.7–0.9). MDMs and AS discerned HGD/esophageal adenocarcinoma from normal esophagus/NDBE in endoscopic brushing and capsule sponge samples. This approach may improve Barrett’s esophagus surveillance. Prevention Relevance: This study demonstrates that combining epigenetic and genomic biomarkers across minimally invasive sampling methods can accurately distinguish HGD/esophageal adenocarcinoma from nondysplastic Barrett’s esophagus, offering promising, less invasive strategies to improve BE surveillance and enable endoscopic therapy for esophageal adenocarcinoma prevention and treatment.